Literature DB >> 2524386

Plasma atrial natriuretic peptide and the renin-aldosterone system during long-term administration of the diuretic xipamide in man.

P Lijnen1, P Hespel, R Fagard, J Staessen, W Goossens, W Lissens, A Amery.   

Abstract

We have studied the effect of xipamide on plasma alpha-atrial natriuretic peptide and the renin-aldosterone-kallikrein system in twelve healthy men, using a double-blind cross-over design. After a run-in period on placebo for 1 week the subjects were treated with either placebo (n = 6) or xipamide 20 mg once daily (n = 6) for 16 weeks and were then switched to the alternative medication for another 16 weeks. The plasma concentration of alpha-atrial natriuretic peptide fell after 1 week of xipamide administration and increased during prolonged xipamide administration but remained suppressed. The changes in plasma alpha-ANP observed after 1 week of xipamide were negatively correlated with the changes in haematocrit and haemoglobin. Plasma renin activity (PRA), aldosterone concentration (PAC), and urinary excretion of aldosterone and kallikrein increased after 1 week of xipamide administration, levelled off during the second and fourth weeks, but remained elevated during further prolonged xipamide administration for 16 weeks. The xipamide-induced changes in PRA and PAC were positively correlated with the changes in the haematocrit and haemoglobin. Our data suggest that the changes in plasma renin, aldosterone, and alpha-atrial natriuretic peptide during xipamide administration may be related to diuretic-induced volume contraction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2524386     DOI: 10.1007/bf00609181

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  28 in total

Review 1.  Atrial natriuretic hormone, the renin-aldosterone axis, and blood pressure-electrolyte homeostasis.

Authors:  J H Laragh
Journal:  N Engl J Med       Date:  1985-11-21       Impact factor: 91.245

2.  Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles.

Authors:  J H Laragh
Journal:  Am J Med       Date:  1973-09       Impact factor: 4.965

3.  Renin-angiotensin-aldosterone system during chronic thiazide therapy of benign hypertension.

Authors:  J J Bourgoignie; F J Catanzaro; H M Perry
Journal:  Circulation       Date:  1968-01       Impact factor: 29.690

Review 4.  Diuretics in hypertension.

Authors:  E D Frohlich
Journal:  J Hypertens Suppl       Date:  1987-08

5.  Effects of auriculin (atrial natriuretic factor) on blood pressure, renal function, and the renin-aldosterone system in dogs.

Authors:  T Maack; D N Marion; M J Camargo; H D Kleinert; J H Laragh; E D Vaughan; S A Atlas
Journal:  Am J Med       Date:  1984-12       Impact factor: 4.965

6.  Direct radioimmunoassay of plasma aldosterone in normal subjects.

Authors:  P Lijnen; A Amery; R Fagard; P Corvol
Journal:  Clin Chim Acta       Date:  1978-03-15       Impact factor: 3.786

Review 7.  The renal kallikrein-kinin system.

Authors:  O A Carretero; A G Scicli
Journal:  Am J Physiol       Date:  1980-04

8.  Decreased urinary kallikrein activity and elevated blood pressure normalized by orally applied kallikrein in essential hypertension.

Authors:  A Overlack; K O Stumpe; C Ressel; R Kolloch; W Zywzok; F Krück
Journal:  Klin Wochenschr       Date:  1980-01-02

Review 9.  Xipamide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.

Authors:  B N Prichard; R N Brogden
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

10.  Effects of synthetic atrial natriuretic factor on renal function and renin release.

Authors:  J C Burnett; J P Granger; T J Opgenorth
Journal:  Am J Physiol       Date:  1984-11
View more
  3 in total

Review 1.  Renal excretory responses to single and repeated administration of diuretics in healthy subjects: clinical connotations.

Authors:  A J Reyes; W P Leary
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

2.  Cicletanine does not affect plasma atrial natriuretic peptide concentration in healthy subjects.

Authors:  I Berlin; G Deray; G Maistre; F Masson; C Barthelemy; J C Legrand; C Jacobs
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Idiopathic Edema: A Case Report.

Authors:  Nikhila Veluri; Karun Badwal
Journal:  Cureus       Date:  2019-07-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.